Table 1 Characteristics of the study design of selected studies of biomarker-based treatment heterogeneity
Characteristic | Number (%a) |
|---|---|
Journalb | |
Ann Oncol | 4 (13) |
Breast Cancer Res | 3 (10) |
Breast Cancer Res Treat | 11 (35) |
Clin Cancer Res | 3 (10) |
Int J Cancer | 5 (16) |
J Clin Oncol | 5 (16) |
Number of patients included in analyses of treatment heterogeneity | |
< 100 | 3 (10) |
100–300 | 10 (32) |
300–500 | 4 (13) |
> 500 | 14 (45) |
Minimum | 42 |
25% quantile | 175 |
Mean (SE) | 851 (192) |
Median | 367 |
75% quantile | 858 |
Maximum | 3746 |
Type of study | |
Randomized | 23 (74) |
Observational | 8 (26) |
Endpoints for which treatment heterogeneity was evaluatedc | |
Binary | 7 (23) |
pCR | 6 (19) |
> 50% relative decrease in 11-gene proliferation signature | 1 (3) |
Time to event | 25 (81) |
Time to progressiond | 25 (81) |
Time to deathe | 9 (29) |
Number of biomarkers for which treatment heterogeneity was evaluated | |
1 | 14 (45) |
2–4 | 10 (32) |
5–10 | 5 (16) |
> 10 | 2 (7) |
Number of endpoints for which treatment heterogeneity was evaluated | |
1 | 21 (68) |
2 | 7 (23) |
3 | 3 (10) |
Median follow up time | |
≤ 5 years | 4 (13) |
5–10 years | 9 (29) |
> 10 years | 2 (6) |
Not applicable | 6 (19) |
Not reported | 10 (32) |